New Mexico Educational Retirement Board Raises Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

New Mexico Educational Retirement Board grew its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 14.3% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 20,842 shares of the medical equipment provider’s stock after purchasing an additional 2,600 shares during the quarter. New Mexico Educational Retirement Board’s holdings in Intuitive Surgical were worth $8,318,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Baystate Wealth Management LLC grew its holdings in shares of Intuitive Surgical by 150.0% during the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 45 shares during the last quarter. MCF Advisors LLC grew its holdings in shares of Intuitive Surgical by 108.1% during the fourth quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 40 shares during the last quarter. Able Wealth Management LLC purchased a new position in shares of Intuitive Surgical during the fourth quarter worth about $28,000. Atticus Wealth Management LLC grew its holdings in shares of Intuitive Surgical by 85.4% during the fourth quarter. Atticus Wealth Management LLC now owns 89 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 41 shares during the last quarter. Finally, MeadowBrook Investment Advisors LLC purchased a new position in shares of Intuitive Surgical during the fourth quarter worth about $30,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Insider Buying and Selling

In other Intuitive Surgical news, Director Alan J. Levy sold 2,000 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the sale, the director now directly owns 25,319 shares of the company’s stock, valued at approximately $9,385,753.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Intuitive Surgical news, Director Alan J. Levy sold 2,000 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the sale, the director now directly owns 25,319 shares of the company’s stock, valued at approximately $9,385,753.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Craig H. Barratt sold 2,496 shares of Intuitive Surgical stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $402.89, for a total transaction of $1,005,613.44. The disclosure for this sale can be found here. Insiders sold 17,956 shares of company stock worth $6,927,011 in the last ninety days. Insiders own 0.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on ISRG shares. Jefferies Financial Group raised their price target on Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a report on Friday, April 19th. Piper Sandler raised their price target on Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a report on Friday, April 19th. The Goldman Sachs Group started coverage on Intuitive Surgical in a report on Thursday, May 30th. They set a “buy” rating and a $500.00 price target on the stock. Robert W. Baird lowered their price target on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating on the stock in a report on Friday, April 19th. Finally, BTIG Research raised their price target on Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a report on Friday, April 19th. Five analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $403.67.

Intuitive Surgical Stock Down 0.1 %

Shares of Intuitive Surgical stock traded down $0.26 during trading on Friday, hitting $444.85. 3,106,192 shares of the company were exchanged, compared to its average volume of 1,372,778. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $447.11. The stock has a market capitalization of $157.79 billion, a price-to-earnings ratio of 80.30, a P/E/G ratio of 5.75 and a beta of 1.39. The firm has a 50 day moving average price of $403.83 and a 200 day moving average price of $383.12.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The firm had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. During the same period in the previous year, the firm posted $1.00 EPS. The company’s quarterly revenue was up 11.5% compared to the same quarter last year. Analysts predict that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.